Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage

医学 重组因子VIIa 凝血病 安慰剂 复苏 钝伤 随机对照试验 止血 耐火材料(行星科学) 临床试验 麻醉 损伤控制手术 外科 输血 重症监护室 重症监护医学 内科学 物理 替代医学 病理 天体生物学
作者
Carl J. Hauser,Kenneth David Boffard,Richard P. Dutton,Gordon R. Bernard,Martin A. Croce,John Bradley Holcomb,Ari Kalevi Leppäniemi,Michael J. Parr,Jean‐Louis Vincent,Bartholomew J. Tortella,Jeannett Dimsits,Bertil Bouillon
出处
期刊:Journal of Trauma-injury Infection and Critical Care [Lippincott Williams & Wilkins]
卷期号:69 (3): 489-500 被引量:374
标识
DOI:10.1097/ta.0b013e3181edf36e
摘要

BACKGROUND: Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes. METHODS: We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We studied 573 patients (481 blunt and 92 penetrating) who bled 4 to 8 red blood cell (RBC) units within 12 hours of injury and were still bleeding despite strict damage control resuscitation and operative management. Patients were assigned to rFVIIa (200 μg/kg initially; 100 μg/kg at 1 hour and 3 hours) or placebo. Intensive care unit management was standardized using evidence-based trauma "bundles" with formal oversight of compliance. Primary outcome was 30-day mortality. Predefined secondary outcomes included blood products used. Safety was assessed through 90 days. Study powering was based on prior randomized controlled trials and large trauma center databases. RESULTS: Enrollment was terminated at 573 of 1502 planned patients because of unexpected low mortality prompted by futility analysis (10.8% vs. 27.5% planned/predicted) and difficulties consenting and enrolling sicker patients. Mortality was 11.0% (rFVIIa) versus 10.7% (placebo) (p = 0.93, blunt) and 18.2% (rFVIIa) versus 13.2% (placebo) (p = 0.40, penetrating). Blunt trauma rFVIIa patients received (mean ± SD) 7.8 ± 10.6 RBC units and 19.0 ± 27.1 total allogeneic units through 48 hours, and placebo patients received 9.1 ± 11.3 RBC units (p = 0.04) and 23.5 ± 28.0 total allogeneic units (p = 0.04). Thrombotic adverse events were similar across study cohorts. CONCLUSIONS: rFVIIa reduced blood product use but did not affect mortality compared with placebo. Modern evidence-based trauma lowers mortality, paradoxically making outcomes studies increasingly difficult.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青的应助被科研通管家采纳,获得10
刚刚
田様的应助被科研通管家采纳,获得10
刚刚
刚刚
田様的应助被科研通管家采纳,获得10
刚刚
刚刚
深情安青的应助被科研通管家采纳,获得30
1秒前
害羞的书芹完成签到,获得积分10
1秒前
CodeCraft的应助被科研通管家采纳,获得10
1秒前
1秒前
共享精神的应助被科研通管家采纳,获得20
1秒前
JamesPei的应助被科研通管家采纳,获得10
1秒前
甜蜜的振家完成签到,获得积分10
1秒前
Ava的应助被科研通管家采纳,获得10
1秒前
Ava的应助被科研通管家采纳,获得10
1秒前
科研通AI65的应助被科研通管家采纳,获得10
2秒前
tianfang完成签到,获得积分10
2秒前
可乐乐完成签到 ,获得积分10
3秒前
Sun完成签到 ,获得积分10
4秒前
dASDA完成签到,获得积分10
5秒前
秋风的应助被gnidam采纳,获得20
6秒前
凌风完成签到,获得积分10
6秒前
扁舟灬完成签到,获得积分10
7秒前
tangtang完成签到 ,获得积分10
8秒前
zaq66996完成签到,获得积分10
10秒前
NN的应助被可乐乐采纳,获得10
10秒前
贾贡献的应助被bjxm采纳,获得10
12秒前
梁瘦瘦完成签到,获得积分10
12秒前
洗月完成签到 ,获得积分10
13秒前
平淡的雨灵完成签到,获得积分10
13秒前
平常的朝雪完成签到 ,获得积分10
14秒前
知识就是力量完成签到 ,获得积分10
14秒前
大力青文完成签到,获得积分10
14秒前
流星发布了新的文献求助10
15秒前
Orange的应助被maclogos采纳,获得10
17秒前
安陌煜完成签到,获得积分10
17秒前
见忧的应助被xiahaijun采纳,获得10
17秒前
852的应助被执着的玉米采纳,获得10
18秒前
周周完成签到,获得积分10
19秒前
xxd完成签到,获得积分10
22秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577518
关于积分的说明 21853016
捐赠科研通 7789293
什么是DOI,文献DOI怎么找? 3436376
关于科研通互助平台的介绍 2560210
邀请新用户注册赠送积分活动 2483032